1.11.21 AFT Pharmaceuticals (NZX.AFT, ASX.AFP) today announced the US Food and Drug Administration (FDA) has confirmed acceptance of the New Drug Application (NDA) for Maxigesic IV®, the intravenous form of its patented pain relief medicine which was filed in August this year. AFT shares jumped 30c to $4.40. The US regulator is expected, in […]